Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome

Status Completed

Clinical Trial Summary

Chronic fatigue syndrome (CFS) is a debilitating condition of unknown etiology. Recent studies have shown that CFS is associated with impaired cellular energetics and low levels of phosphocreatine. Since guanidinoacetic acid (GAA) acts as a highly bioavailable precursor of creatine it may provide an ideal dietary supplement to facilitate treatment and perhaps prevention of CFS. The overall hypothesis to be evaluated is that medium-term supplementation with GAA will improve clinical outcomes in well-defined adult CFS patients via augmented provision of creatine. Specific aims: (1) To determine the effects of GAA on CFS symptomatology using a fatigue severity inventory, soreness of locomotive apparatus scales, and a health-related quality of life survey; (2) To determine the effect of GAA on creatine metabolism using laboratory studies and magnetic resonance spectroscopy; (3) To characterize the physiological effects of GAA on work capacity via actigraphy and exercise performance tests; and (4); To determine the prevalence of subjectively reported side-effects and biochemical adverse events associated with GAA intervention.

Clinical Trial Description

A variety of dietary interventions have been used in the management of CFS, yet no therapeutic modality demonstrated overall positive results in terms of effectiveness (Whiting et al. 2001). Previous studies have evaluated the effects of essential fatty acids, vitamins, minerals and/or enzymes, with findings do not support the use of a broad-spectrum nutritional supplement in treating CFS‐related symptoms (Brouwers et al. 2002). Considering the fact that patients with CFS have lower levels of high-energy compounds (e.g. phosphocreatine, adenosine triphosphate) (Block et al. 1998), effective dietary treatment of CFS should be focused on providing compounds that facilitates cellular bioenergetics. Besides other candidate agents, guanidinoacetic acid (GAA) could be of particular interest since it occurs naturally in the human body and acts as an immediate precursor of creatine (Wyss and Kaddurah-Daouk, 2000). Due to its low cost and high bioavailability (Baker 2009), if proven effective dietary GAA may be suitable for use in broad CFS population. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02213679
Study type	Interventional
Source	Center for Health, Exercise and Sport Sciences, Serbia
Contact
Status	Completed
Phase	N/A
Start date	August 2014
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05454683` - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	N/A
Completed	`NCT01686074` - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia	N/A
Completed	`NCT02075489` - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans	N/A
Completed	`NCT01651754` - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome	N/A
Completed	`NCT00540254` - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome	Phase 1/Phase 2
Active, not recruiting	`NCT00071162` - Genetics of Fibromyalgia	N/A
Withdrawn	`NCT04870476` - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome	N/A
Completed	`NCT05730660` - Quercetin Phytosome® Chronic Fatigue Syndrome	N/A
Recruiting	`NCT04542161` - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Phase 2
Recruiting	`NCT03807973` - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Phase 1
Recruiting	`NCT05719493` - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)	N/A
Recruiting	`NCT05967052` - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation	Phase 2
Terminated	`NCT01730495` - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01156909` - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01650636` - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process	N/A
Completed	`NCT01046370` - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia	N/A
Completed	`NCT00100412` - Hyporeactivity and Gulf War Illness	N/A
Recruiting	`NCT06128967` - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial	Phase 3
Completed	`NCT02669212` - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health	N/A
Not yet recruiting	`NCT06011135` - Exploring Worry in CFS/ME